Kratom dependence can be difficult to recognize because products sold under the kratom name can differ substantially. Someone may begin with traditional kratom powder or capsules and later progress to concentrated extracts, liquid shots, enhanced products, or high-potency 7-hydroxymitragynine products commonly called 7-OH. Although these products are often marketed together, their potency, composition, and withdrawal effects may be very different.
Brooks Healing Center provides kratom addiction treatment in Tennessee for adults struggling with traditional kratom, kratom extracts, 7-OH products, and related patterns of substance use. Located in Normandy between Nashville and Chattanooga, Brooks provides medically supported detox, residential addiction treatment, evidence-based therapy, individualized medication assessment when clinically appropriate, and continued treatment through our Partial Hospitalization Program (PHP).
If you are taking kratom or 7-OH every day, using primarily to prevent withdrawal, repeatedly trying and failing to stop, or finding that you need increasing amounts just to feel normal, you do not have to determine the appropriate treatment level on your own. Brooks’ admissions team can help evaluate what you have been using and discuss the next appropriate step.
Table of Contents
Key Points About Kratom Addiction and Treatment
- Kratom contains opioid-active alkaloids. Mitragynine and 7-hydroxymitragynine are among the compounds receiving the greatest research attention, although kratom has pharmacological effects beyond the opioid system.
- Regular kratom use can cause physical dependence. Tolerance, cravings, withdrawal, unsuccessful attempts to stop, and other symptoms associated with substance use disorders have been documented among some frequent users.
- Traditional kratom and concentrated 7-OH products are not interchangeable. Extracts and enhanced products can produce substantially different exposure from traditional whole-leaf material.
- Kratom is illegal in Tennessee. Since July 1, 2026, Tennessee has prohibited possession, manufacture, and sale of kratom, including products made from the plant.
- A ban does not eliminate dependence. Tennesseans who had already become dependent may still experience withdrawal or cravings and can encounter kratom, 7-OH, or related products while traveling to jurisdictions where laws and availability differ.
- There is no FDA-approved medication specifically for kratom dependence or problematic kratom use. Medication decisions should be individualized, particularly when significant dependence, 7-OH exposure, or a separate opioid use disorder is present.
- How Brooks helps: Brooks provides supervised withdrawal management, residential treatment, individualized therapy, medication assessment when clinically appropriate, support for co-occurring mental health concerns, PHP, supportive housing, sober living, and continuing recovery planning.
Kratom Addiction Treatment at a Glance
| Brooks Program / Level of Care | What It Provides | When It May Be Appropriate |
|---|---|---|
| Medical Detox | Supervised assessment, withdrawal monitoring, stabilization, symptom management, and individualized medication evaluation. | When withdrawal, high-potency products, polysubstance use, repeated difficulty stopping, or other medical or mental health concerns make structured support appropriate. |
| Residential Treatment | 24-hour structured addiction treatment with therapy, clinical support, recovery education, and relapse-prevention planning. | When kratom or 7-OH use has become difficult to interrupt outside treatment or someone needs continued structure after withdrawal. |
| Medication Assessment | Individualized evaluation of whether medication has an appropriate role in treatment. | When withdrawal is significant, high-potency opioid-active products are involved, or a separate opioid use disorder is present. |
| Partial Hospitalization Program (PHP) | Intensive daytime clinical treatment with therapy, medication follow-up when appropriate, and increasing independence. | Following residential treatment or when someone is medically stable but continues to need substantial treatment structure. |
| Sober Living | Structured, substance-free housing with accountability, routines, peer support, and greater independence. | For eligible individuals who no longer require intensive treatment but continue to benefit from recovery-focused housing. |
What Is Kratom?
Kratom is the common name for Mitragyna speciosa, a tree native to Southeast Asia. Its leaves contain numerous naturally occurring alkaloids, with mitragynine and 7-hydroxymitragynine among the most widely studied.
Kratom can produce a range of effects. People report stimulant-like effects such as increased energy and alertness as well as opioid-like effects such as relaxation and reduced pain. The effects are not completely predictable according to a simple dose range because product composition, alkaloid concentration, preparation, and individual response can vary considerably. NCCIH
People report using kratom for pain, fatigue, anxiety, mood symptoms, opioid cravings, or opioid withdrawal. However, there are currently no FDA-approved medical uses for kratom, including for pain, anxiety, depression, opioid withdrawal, or opioid use disorder. U.S. Food and Drug Administration
Kratom is also sometimes grouped together with plant-based products such as kava even though the substances work differently. Brooks’ Kava vs. Kratom guide explains the differences in their effects, mechanisms, dependence potential, and safety considerations.
For some people, what begins as occasional or self-directed use eventually becomes repeated dosing simply to prevent withdrawal or feel normal.
Kratom vs. Extracts vs. 7-OH Products
One of the most important changes in the kratom market is that the word “kratom” no longer necessarily describes one type of exposure.
Traditional botanical kratom contains numerous naturally occurring alkaloids and only trace or relatively small amounts of 7-OH. Extracts can concentrate mitragynine and other alkaloids beyond the concentrations found in ordinary leaf material. Commercial 7-OH products go further by delivering enhanced levels of 7-hydroxymitragynine in tablets, gummies, shots, drink mixes, strips, and other formulations.
The FDA distinguishes traditional botanical kratom from products containing 7-OH as an added ingredient or at enhanced levels. FDA currently characterizes those concentrated 7-OH products as potent opioid products that have not been demonstrated to be safe or effective for medical use. U.S. Food and Drug Administration
Newer compounds related to kratom chemistry have also entered the marketplace. That makes it increasingly important for patients to tell their treatment team the actual product, formulation, frequency, and amount they have been using instead of simply reporting that they take “kratom.”
Kratom, 7-OH, and Related Products: What's the Difference?
| Kratom-Related Product | What It Is | Dependence & Treatment Considerations | Current Status |
|---|---|---|---|
| Traditional Kratom | Botanical Mitragyna speciosa leaf containing naturally occurring mitragynine, trace 7-OH, and other alkaloids. | Frequent use can lead to tolerance, physical dependence, withdrawal, cravings, and problematic patterns of use in some people. | Not federally scheduled as botanical kratom; possession, manufacture, and sale are prohibited in Tennessee. |
| Kratom Extracts | Concentrated products that may substantially increase exposure to kratom alkaloids compared with traditional leaf. | Increased potency and frequent dosing may contribute to escalating tolerance, dependence, and withdrawal. | Federal treatment depends partly on composition; Tennessee’s kratom prohibition applies. |
| 7-Hydroxymitragynine (7-OH) | An opioid-active alkaloid that naturally occurs in kratom in small amounts but is now sold in concentrated or enhanced commercial products. | Concentrated products may produce significant dependence, withdrawal, and other opioid-related harms. | DEA initiated a separate federal process in 2026 to temporarily schedule 7-OH above a specified concentration threshold; ordinary botanical kratom below that threshold was distinguished from concentrated products. DEA |
| Mitragynine Pseudoindoxyl (MGPI) | A potent opioid-active compound chemically related to mitragynine and 7-OH. | Human evidence remains limited, but opioid activity raises concerns about dependence, withdrawal, and overdose. | Temporarily placed in federal Schedule I in August 2026. |
| MGM-15 | A manufactured opioid compound related to 7-OH chemistry. | Human safety data remain limited, with significant concern because of opioid-receptor activity. | Temporarily placed in federal Schedule I in August 2026. |
| MGM-16 | Another manufactured compound in the same emerging 7-OH-related market. | Human data remain limited and the full risk profile is still developing. | Temporarily placed in federal Schedule I in August 2026. |
The Justice Department announced emergency Schedule I placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in August 2026. The separate federal process involving 7-OH above a specified threshold should not be confused with that completed scheduling action. Department of Justice
Brooks provides additional resources on 7-OH withdrawal, mitragynine pseudoindoxyl vs. 7-OH, MGM-15, and MGM-15 vs. MGM-16.
Kratom Is Now Illegal in Tennessee
As of July 1, 2026, Tennessee prohibits the possession, manufacture, and sale of kratom. The state’s 2026 law expanded the prohibition to include the plant itself and products manufactured from it, including powders, capsules, gummies, liquid shots, extracts, and other forms. Tennessee State Government
Brooks maintains a more detailed Kratom and 7-OH Ban by State guide because kratom and 7-OH laws continue to change substantially between jurisdictions.
Federal regulation is developing separately from Tennessee law. The DEA announced federal action involving concentrated 7-OH and several related compounds during 2026, but botanical kratom, concentrated 7-OH, and newly manufactured derivatives should not be treated as legally interchangeable categories. DEA
What Tennessee's Kratom Ban Means for People Already Dependent
A change in legal availability does not immediately eliminate physical dependence. Someone who had been taking kratom, extracts, or 7-OH regularly before the law changed may still experience cravings, anxiety, sleep disruption, gastrointestinal symptoms, muscle discomfort, or other withdrawal symptoms when access suddenly stops.
The ban also does not mean Tennesseans will never encounter these substances again. State laws differ, including in states within driving distance of Tennessee, and someone struggling with dependence may seek kratom, concentrated 7-OH, or related products while traveling. Bringing prohibited kratom back into Tennessee does not make possession lawful, but changing where a substance is sold does not automatically eliminate the underlying addiction or craving.
For someone who had been relying on kratom to manage pain, anxiety, opioid withdrawal, stress, energy, sleep, or another concern, treatment should address both the dependence and the reason repeated use developed.
The Kratom Market Is Changing Quickly
The modern kratom market extends well beyond dried leaves, capsules, and powder. Consumers may encounter enhanced extracts, concentrated 7-OH tablets, vape-style products, chemically modified compounds, and products marketed as alternatives to kratom or 7-OH even when they act on similar opioid pathways.
Delivery methods are changing as well. Products promoted as 7-OH vapes illustrate how the market has moved into formats that look increasingly different from the powders and capsules traditionally associated with kratom.
Tennessee’s ban reduces legal access within the state, but it does not eliminate the risk to Tennesseans who already have an established dependence. Someone experiencing cravings or withdrawal may travel to another jurisdiction where different laws apply, order or seek substitute products, or move toward a newer compound marketed under a different name.
That makes product identification increasingly important. Treatment should begin by asking what the person has actually been taking, where it came from, what the packaging says, how frequently it is used, what effects it produces, and what happens when the person stops rather than assuming every person who says “kratom” has been exposed to the same substance.
Cat's Claw and Disguised Opioid-Active Products
Cat’s claw is a separate botanical and is not another name for kratom or 7-OH. However, Utah public-health and agricultural officials issued a warning in July 2026 after laboratory testing of Buzzers-brand products labeled as Cat’s Claw detected mitragynine pseudoindoxyl and MGM-15, two opioid-active compounds associated with the evolving kratom-derived market. Utah Department of Agriculture and Food
Brooks has also documented similarly branded products appearing in Middle Tennessee after restrictions on kratom and 7-OH intensified. That local observation does not establish that every product marketed as Cat’s Claw contains an undisclosed opioid or that locally observed products contain the same ingredients as the laboratory-confirmed Utah products.
The larger concern is that the product name alone may not reliably communicate what someone is taking. Brooks covers the issue in detail in Cat’s Claw or 7-OH in Disguise? What Tennessee Needs to Know About Mislabeled Opioid Products.
Is Kratom Addictive?
Regular kratom use can lead to tolerance, physical dependence, cravings, withdrawal, and problematic patterns of continued use in some people. The research term “kratom use disorder” is not a separately named diagnosis in the DSM-5-TR. Clinicians can assess problematic kratom use using broader substance-use-disorder criteria, considering the person’s symptoms, impaired control, and effects on daily life rather than treating the product name as a diagnosis. PubMed Central (PMC)
Research involving regular kratom consumers has found symptoms such as withdrawal or use to avoid withdrawal, tolerance, craving, taking more than intended, and unsuccessful attempts to reduce use. Importantly, greater frequency of dosing was more strongly associated with withdrawal and other symptoms of problematic use than dose amount alone in a 2024 study of U.S. kratom consumers. PubMed Central (PMC)
This is one reason someone taking repeated doses throughout the day may have a very different clinical presentation from someone using traditional leaf occasionally.
Physical Dependence vs. Kratom Addiction
Physical dependence and addiction are related concepts, but they are not identical. Physical dependence means that the body has adapted to regular exposure and symptoms can develop when the substance is reduced or stopped.
A clinically significant substance-use pattern involves a broader picture. Cravings, loss of control, unsuccessful efforts to stop, escalating use, continued use despite consequences, and the degree to which kratom begins disrupting health, relationships, responsibilities, finances, or daily functioning all matter when determining the severity of the problem.
Signs Kratom Use May Have Become a Problem
Possible warning signs include:
- Needing kratom, extracts, or 7-OH every day to feel normal
- Taking increasingly frequent or larger doses
- Waking during the night or early morning because withdrawal begins
- Experiencing cravings or anxiety when the product is unavailable
- Repeatedly trying to reduce or stop without succeeding
- Taking kratom primarily to make withdrawal symptoms disappear
- Spending increasing amounts of money on powders, extracts, shots, tablets, or 7-OH
- Hiding the amount or frequency of use from family members
- Continuing despite physical, emotional, financial, occupational, or relationship problems
- Progressing toward increasingly concentrated products because traditional kratom no longer has the desired effect
- Returning to kratom after previous attempts to stop
- Combining kratom or 7-OH with opioids, alcohol, benzodiazepines, or other drugs
Someone does not need to experience every sign before asking for help. A pattern of escalating frequency, dependence, withdrawal, inability to cut back, or continued use despite harm can be enough reason to seek an assessment.
Kratom Withdrawal
Withdrawal can occur after regular kratom use once physical dependence has developed. The intensity of symptoms varies according to factors such as frequency of dosing, duration of use, product potency, total exposure, the type of product involved, and use of other substances.
Kratom withdrawal is often described as sharing some features with opioid withdrawal, but individual experiences vary considerably. Research conducted primarily on traditional kratom users also may not completely predict withdrawal from today’s concentrated 7-OH or newly manufactured products. PubMed
Kratom Withdrawal Symptoms
Reported symptoms can include:
- Strong cravings
- Anxiety
- Irritability or agitation
- Difficulty sleeping
- Restlessness or restless legs
- Low energy
- Fatigue
- Depressed or low mood
- Muscle aches or discomfort
- Twitching or spasms
- Sweating
- Hot and cold sensations
- Runny nose
- Watery eyes
- Reduced appetite
- Abdominal discomfort
- Nausea
- Diarrhea
A 2024 study found craving, low energy, irritability, fatigue, and anxiety among commonly reported symptoms after missed or discontinued doses, with withdrawal risk increasing alongside more frequent dosing. PubMed Central (PMC)
High-concentration 7-OH may produce a more opioid-like dependence and withdrawal experience than traditional botanical kratom. Brooks’ 7-OH Withdrawal: Symptoms, Duration, and What Actually Helps provides a separate discussion of those concentrated products.
How Long Does Kratom Withdrawal Last?
There is no single kratom withdrawal timeline that applies to everyone. Published reports describe symptoms beginning within approximately the first day or two after discontinuing regular use for some patients, while the most noticeable acute symptoms may improve over several days in many traditional-kratom cases. PubMed
Frequency, product concentration, duration of use, individual physiology, and other substances can alter that course. Someone repeatedly taking high-potency 7-OH throughout the day should not automatically expect the same withdrawal experience described in older research involving traditional botanical material.
For this reason, Brooks evaluates the individual rather than promising a fixed kratom detox timeline.
Withdrawal timeline disclaimer: The timing described above is an illustrative example, not a prediction or a guaranteed detox schedule. Symptoms, onset, severity, and duration can vary widely according to the product and its potency, dosing frequency, duration of use, other substances, health conditions, and individual response. Concentrated extracts and 7-OH products may follow a different course from traditional kratom. Some symptoms can persist beyond these ranges. A clinician should assess your situation rather than relying on this example to decide when withdrawal is over or whether it is safe to manage at home.
Is Kratom Withdrawal Dangerous?
For many people, kratom withdrawal is uncomfortable rather than inherently life-threatening, but that does not mean every case is appropriate to manage without clinical support. Significant vomiting or diarrhea, dehydration, serious medical conditions, psychiatric instability, pregnancy, or simultaneous withdrawal from alcohol or benzodiazepines can change the risk considerably.
Uncertainty about the product itself also matters. Someone using concentrated 7-OH, an unidentified extract, or a newer opioid-active derivative may have a substantially different clinical picture than someone using traditional leaf.
Difficulty tolerating withdrawal can also lead someone to return rapidly to use or substitute another substance simply to make symptoms stop. A history of opioid use disorder, fentanyl exposure, polysubstance use, or previous unsuccessful attempts to discontinue kratom should therefore be part of the assessment.
Can Symptoms Continue After Acute Kratom Withdrawal?
Physical withdrawal does not necessarily mark the end of every symptom. Some people report continued sleep disruption, cravings, low mood, reduced motivation, anxiety, cognitive difficulty, or greater sensitivity to stress after the most obvious acute symptoms have improved.
These longer-lasting symptoms are sometimes discussed under the broader concept of post-acute withdrawal syndrome (PAWS). However, PAWS is not a kratom-specific DSM-5-TR diagnosis, and research defining a distinct prolonged kratom withdrawal syndrome remains limited, so persistent symptoms should be evaluated individually rather than automatically attributed to PAWS.
Kratom Detox at Brooks Healing Center
Medical detox at Brooks Healing Center provides a supervised setting where withdrawal symptoms and other clinical needs can be assessed while someone stops kratom, concentrated extracts, 7-OH, or related substances.
Detox begins with an individualized assessment rather than assuming every kratom product produces the same withdrawal pattern. The clinical team considers the actual products involved, frequency and duration of use, previous withdrawal experiences, other substances, medications, medical history, mental health symptoms, and the person’s previous treatment history.
The goal of detox is stabilization, not simply reaching a certain number of days without kratom. Once someone is physically and emotionally stable enough, treatment can begin addressing the behavioral, psychological, and environmental factors connected with continued use.
Can You Detox From Kratom at Home?
Some people experience relatively mild symptoms when stopping traditional kratom, while others repeatedly return to use because withdrawal becomes difficult to tolerate. It can be especially hard to predict the course when concentrated extracts, 7-OH, alcohol, benzodiazepines, opioids, or multiple substances are involved.
A professional assessment can help determine whether medical detox is appropriate based on substance-use history, medical health, mental health, previous withdrawal, current medications, available support, and current symptoms. For someone with substantial dependence or a previous opioid use disorder, attempting repeated withdrawal without a continuing treatment plan may also increase the risk of substituting another substance.
When Is Medical Kratom Detox Appropriate?
Structured detox may be appropriate when factors such as these are present:
- Frequent daily kratom or 7-OH use
- Repeated dosing throughout the day
- High-potency extracts or concentrated products
- Significant withdrawal symptoms
- Repeated unsuccessful attempts to stop
- Previous opioid use disorder
- Alcohol or benzodiazepine dependence
- Polysubstance use
- Significant medical conditions
- Co-occurring psychiatric symptoms
- Uncertainty about what a product actually contains
- An unsafe or unstable home environment
The presence of one factor does not automatically determine a level of care. Treatment recommendations should be based on the complete clinical picture.
What Happens During Kratom Detox?
A kratom detox assessment may consider:
- Traditional kratom versus extract or 7-OH use
- Specific product names and formulations
- How frequently products are taken
- How long use has continued
- Withdrawal between doses
- Previous attempts to stop
- Other opioid exposure
- Alcohol or benzodiazepine use
- Stimulants or other substances
- Current prescription medications
- Medical conditions
- Mental health symptoms
- Previous treatment
- Available recovery support
Clinical monitoring can then be adjusted according to what symptoms actually develop. This is particularly important in the current market because a person may use the word “kratom” to describe exposures ranging from traditional powder to highly concentrated opioid-active products.
Medication Support During Kratom Withdrawal
There is currently no FDA-approved medication specifically for kratom dependence, problematic kratom use, or kratom withdrawal. That distinction should remain clear even though kratom and several kratom-related compounds interact with opioid receptors. PubMed Central (PMC)
Published clinical reports describe the use of medications including buprenorphine in selected patients with significant kratom dependence. However, the evidence consists largely of case reports and observational clinical experience rather than controlled trials establishing a standard medication protocol for kratom-related problems without a co-occurring opioid use disorder. PubMed Central (PMC)
The situation is different when someone independently meets criteria for opioid use disorder. FDA-approved medications for OUD have an established evidence base, and treatment of the underlying OUD remains important even when kratom or 7-OH is also being used.
Brooks can provide individualized medication assessment when clinically appropriate. Medication decisions are made according to the person’s diagnoses, withdrawal pattern, prior opioid exposure, medical history, and overall treatment needs rather than automatically because someone reports kratom use.
When buprenorphine is being considered around opioid-receptor-active substances, appropriate timing and clinical evaluation also matter. Brooks’ guide to precipitated withdrawal explains why medication initiation should be individualized.
Treating 7-OH Dependence
High-potency 7-OH has changed the kratom treatment landscape. Although 7-hydroxymitragynine occurs naturally in kratom in small amounts, commercial products can contain enhanced concentrations that bear little resemblance to traditional leaf exposure.
FDA has warned consumers about products containing added or enhanced 7-OH because of their potent opioid activity, addiction and withdrawal potential, and reports of serious adverse effects. The agency distinguishes these concentrated products from the trace 7-OH naturally occurring in botanical kratom. U.S. Food and Drug Administration
For treatment purposes, Brooks therefore evaluates exactly what someone has been using rather than assuming a product marketed as kratom is ordinary leaf.
How 7-OH Withdrawal Can Differ From Traditional Kratom Withdrawal
Someone using high-potency 7-OH repeatedly throughout the day can experience a different degree of opioid-receptor exposure from someone using traditional kratom leaf once or twice daily. Rapid tolerance, severe cravings, dosing soon after waking, withdrawal between doses, and repeated use simply to feel normal can all suggest significant physical dependence.
There is not enough evidence to establish one universal 7-OH withdrawal timeline or to assume every commercial product has the same potency. The product formulation, amount, frequency, duration, and presence of other compounds all need to be considered.
Brooks provides a dedicated 7-OH withdrawal and treatment resource for people using concentrated products.
Residential Kratom Addiction Treatment
Detox addresses immediate withdrawal and stabilization, but it does not automatically address what caused regular kratom or 7-OH use to continue.
After stabilization, some patients benefit from residential addiction treatment at Brooks on our 36-acre Normandy campus. Residential treatment provides distance from the routines, environments, access points, and triggers associated with repeated substance use while allowing the patient to focus on the broader recovery process.
One person may have begun using kratom because of chronic stress. Another may have been attempting to manage pain, anxiety, sleep problems, or previous opioid withdrawal. Someone else may have started with traditional powder before progressing toward concentrated extracts or 7-OH as tolerance increased.
Those differences matter because effective addiction treatment needs to address more than the product itself.
Why Treatment May Need to Continue After Detox
Completing withdrawal does not automatically resolve cravings, coping patterns, co-occurring mental health symptoms, environmental triggers, or the reasons someone repeatedly returned to kratom.
Continued treatment may address:
- Cravings and relapse patterns
- Emotional regulation
- Distress tolerance
- Anxiety and depression
- Trauma and grief
- Stress management
- Sleep and routine
- Chronic pain concerns
- Relationships and boundaries
- Previous opioid use
- Recovery support
- Planning for legal and market changes around kratom and 7-OH
- Developing alternative ways to respond to discomfort without substance use
The goal is not simply to create abstinence inside a controlled environment. Treatment should help prepare the patient for the stressors and triggers that return outside treatment.
Therapy for Problematic Kratom Use
Brooks uses individualized treatment planning rather than one standardized therapy for every patient. Depending on clinical need, treatment may incorporate behavioral therapies, trauma-informed care, experiential approaches, individual counseling, group therapy, peer recovery support, and relapse-prevention planning.
Treatment can explore how kratom use relates to anxiety, depression, trauma, chronic stress, pain, previous opioid use, sleep difficulty, relationships, or other factors that contributed to repeated use. The objective is not simply to tell someone to stop taking kratom; it is to develop healthier ways of responding to the circumstances that previously led back to use.
Cognitive Behavioral Therapy and Relapse Prevention
Cognitive Behavioral Therapy (CBT) can help patients identify relationships between thoughts, emotions, triggers, cravings, and substance use. Patients can then practice alternative responses before a craving or uncomfortable emotion turns into automatic use.
Relapse-prevention planning can also identify high-risk situations such as easy product access, travel to states where kratom remains available, online marketing, chronic pain flares, sleep disruption, conflict, or withdrawal-related fears.
Emotional Regulation and Distress Tolerance
When kratom has become a quick way of managing anxiety, stress, discomfort, anger, or emotional overload, simply removing the substance may leave the original problem untreated.
Dialectical Behavior Therapy (DBT) and related skills can help patients practice distress tolerance, emotional regulation, mindfulness, and healthier responses to intense urges.
Trauma-Informed and Experiential Treatment
For some patients, trauma or grief contributes to substance use, although trauma should not automatically be assumed to explain every kratom problem. Trauma-informed treatment allows these concerns to be addressed safely when relevant.
Experiential therapy can provide additional ways to work on emotional awareness, communication, coping, and relationships outside a traditional talk-therapy setting.
Can Kratom or 7-OH Cause an Overdose?
The safety picture differs significantly between traditional kratom, concentrated 7-OH products, newly manufactured derivatives, and situations involving multiple drugs.
Available NIH information indicates that fatal overdose involving traditional kratom alone appears to be uncommon, but serious adverse effects have been reported, including seizures, cardiovascular problems, liver injury, loss of consciousness, and other complications. Newer U.S. poison-center data also show rising numbers of serious kratom-associated exposures, with multiple substances involved in most reported deaths. NCCIH; CDC
Risk can increase substantially when kratom or 7-OH is combined with opioids, alcohol, benzodiazepines, other sedatives, stimulants, prescription medications, or unidentified ingredients. Brooks’ combined drug intoxication guide explains why polysubstance exposure can make medical effects much harder to predict.
FDA has separately warned that enhanced 7-OH products can cause serious harm, including addiction and withdrawal symptoms. U.S. Food and Drug Administration
If someone is unconscious, cannot be awakened, has slowed or abnormal breathing, experiences a seizure, or otherwise appears to be experiencing an overdose or medical emergency, call 911 immediately.
Tennessee behavioral-health officials also advise giving naloxone if it is available when overdose is suspected, because an opioid may be involved and naloxone may help with some harmful effects while emergency medical care is on the way. Stay with the person and follow 911 instructions. Tennessee State Government
Treatment for Kratom and Other Substance Use
Kratom use does not always occur by itself. Some people begin using kratom after previous opioid use, while others combine kratom, 7-OH, or extracts with prescription opioids, fentanyl, benzodiazepines, alcohol, stimulants, marijuana, or other substances.
Treatment therefore needs to look beyond the product that first brings someone into care. Someone experiencing both kratom dependence and opioid use disorder may need a very different treatment plan from a person whose substance use is limited to traditional kratom.
When anxiety, depression, trauma-related symptoms, PTSD, mood symptoms, grief, sleep disruption, or other mental health concerns are also present, Brooks can address appropriate co-occurring needs through dual-diagnosis treatment when those conditions can be safely managed within our addiction-treatment setting.
Continuing Care After Residential Treatment
Recovery does not end when withdrawal resolves or residential treatment is completed. Some people need an extended period of structure as they begin applying recovery skills outside a 24-hour residential environment.
Depending on clinical needs, patients may transition into Brooks’ Partial Hospitalization Program while continuing therapy, medication follow-up when appropriate, relapse-prevention planning, and support for co-occurring mental health needs.
Partial Hospitalization and Supportive Housing
PHP provides intensive daytime clinical care while allowing greater independence outside treatment hours. For eligible patients who need a structured place to live while participating in PHP, Brooks provides supportive housing in Tullahoma.
The appropriate transition depends on progress in treatment, medical and clinical needs, relapse risk, living environment, available support, and the patient’s individualized recovery plan.
Sober Living and Long-Term Recovery
For eligible individuals who no longer require intensive clinical treatment but continue to benefit from structure and accountability, Brooks also provides sober living in Tullahoma.
Recovery planning can also include outpatient clinical care through appropriate providers, peer support, family support, medication follow-up, community recovery resources, and a clear plan for managing cravings or unexpected exposure to kratom and related products.
Why Choose Brooks for Kratom Rehab in Tennessee?
Brooks Healing Center is located at 1100 Cortner Road in Normandy, Tennessee, on a 36-acre campus between Nashville and Chattanooga.
Brooks is accredited by The Joint Commission and licensed by the Tennessee Department of Mental Health and Substance Abuse Services. Current state licenses for the Normandy campus include residential detoxification and residential rehabilitation services, allowing clinically appropriate patients to move from detox into continued residential addiction treatment within the Brooks continuum.
Treatment is individualized around the person rather than a product name. This is particularly important with kratom because two people who both describe themselves as “addicted to kratom” may actually be using completely different products and may have very different levels of physical dependence, opioid exposure, mental health needs, polysubstance use, and treatment histories.
Brooks’ continuum may include:
- Medical detox and stabilization
- Residential addiction treatment
- Medication assessment when clinically appropriate
- Treatment of an existing opioid use disorder when applicable
- Individual and group therapy
- Cognitive Behavioral Therapy
- Dialectical Behavior Therapy
- Trauma-informed treatment
- Experiential therapy
- Support for appropriate co-occurring mental health concerns
- Relapse-prevention planning
- Partial Hospitalization Program
- Supportive housing
- Sober living
- Continuing recovery planning
Patients and families can also verify insurance benefits before admission.
Does Insurance Cover Kratom Addiction Treatment?
Insurance coverage for substance use disorder treatment depends on the individual health plan, medical necessity, recommended level of care, network status, deductible, coinsurance, and authorization requirements.
Coverage generally is not determined simply by the product name someone has been using. Admissions and clinical assessment help establish the treatment needs involved, and Brooks can contact the insurer to verify benefits before admission.
Insurance verification does not guarantee payment, but it can help patients and families better understand the benefits available under a particular plan.
Get Help for Kratom or 7-OH Addiction in Tennessee
Kratom dependence does not have to look exactly like another person’s addiction before it deserves attention. If you are taking kratom, extracts, or 7-OH primarily to avoid withdrawal, have tried unsuccessfully to stop, or have watched the amount and frequency of your use continue to increase, an assessment can help determine what level of care is appropriate.
Brooks Healing Center provides kratom and 7-OH addiction treatment in Tennessee through medically supported detox, residential care, individualized therapy, medication assessment when clinically appropriate, PHP, supportive housing, sober living, and continued recovery planning.
Call Brooks Healing Center at 931-486-8824 to speak with admissions.
Frequently Asked Questions About Kratom Addiction Treatment
Is kratom addictive?
Kratom can cause physical dependence, tolerance, cravings, withdrawal, and clinically significant patterns of problematic use in some people. “Kratom use disorder” is a term used in research, not a separately named diagnosis in the DSM-5-TR. Clinical assessment considers broader substance-use-disorder criteria and the individual’s symptoms and functioning. PubMed Central (PMC)
The risk appears to increase with more frequent use, and dependence may become especially significant when someone progresses toward extracts, high-potency 7-OH, or repeated dosing throughout the day.
Is kratom an opioid?
Kratom is a botanical substance rather than a conventional pharmaceutical or illicit opioid such as oxycodone, heroin, or fentanyl. However, important kratom alkaloids interact with opioid receptors, which helps explain why some of its effects, dependence patterns, and withdrawal symptoms can resemble opioid effects.
The distinction becomes more complicated with concentrated 7-OH and manufactured kratom-related compounds. FDA describes concentrated 7-OH products as potent opioid products, so these should not simply be treated as equivalent to traditional botanical kratom. U.S. Food and Drug Administration
Is kratom legal in Tennessee?
No. As of July 1, 2026, Tennessee prohibits possession, manufacture, and sale of kratom, including whole-leaf manufactured products. Tennessee State Government
State laws elsewhere vary, and Brooks maintains an updated state-by-state kratom and 7-OH law guide.
Does Tennessee's kratom ban mean the addiction risk is gone?
No. A person who had already developed physical dependence can still experience cravings and withdrawal after retail access changes.
Tennesseans may also encounter kratom, 7-OH, or related products while traveling to states with different laws, and the marketplace can move toward alternative compounds or misleadingly branded products. Treatment addresses the dependence and pattern of use rather than assuming legal prohibition automatically ends the problem.
What is 7-OH?
7-OH is short for 7-hydroxymitragynine, an opioid-active alkaloid associated with kratom. It occurs naturally in small amounts in botanical kratom, but commercial manufacturers have sold products containing added or substantially enhanced concentrations.
FDA has warned that these high-concentration products are fundamentally different from ordinary botanical exposure and can cause addiction, withdrawal, and other serious harm. U.S. Food and Drug Administration
Are Cat's Claw products the same as kratom or 7-OH?
No. Genuine cat’s claw is a separate botanical.
The concern arose because Utah officials tested certain Buzzers-brand tablets marketed as Cat’s Claw and detected mitragynine pseudoindoxyl and MGM-15. That finding applies to the tested products and should not be interpreted to mean every Cat’s Claw supplement contains opioid-active substances. Utah Department of Agriculture and Food
Brooks explains the issue further in Cat’s Claw or 7-OH in Disguise?.
What are MGM-15 and MGM-16?
MGM-15 and MGM-16 are manufactured compounds related to the rapidly evolving 7-OH market and should not be confused with ordinary kratom leaf. Human safety information remains limited.
The federal government temporarily placed MGM-15 and MGM-16, along with mitragynine pseudoindoxyl, into Schedule I in August 2026. Department of Justice
How long does kratom withdrawal last?
There is no universal timeline. Symptoms can begin during the first day or two after cessation in some regular users, and acute symptoms may improve over several days, although sleep problems, cravings, mood symptoms, and other effects can continue longer.
Product potency, frequency of dosing, duration of use, other substances, and individual physiology can all affect the withdrawal course. PubMed
Is 7-OH withdrawal different from traditional kratom withdrawal?
It can be. Commercial concentrated 7-OH products can produce substantially greater opioid-active exposure than ordinary botanical kratom.
Someone using high-potency 7-OH frequently may therefore develop a more opioid-like pattern of physical dependence and withdrawal. Because products vary greatly, withdrawal should be assessed individually rather than predicted only from the word “7-OH.”
Can I detox from kratom at home?
Some people experience relatively mild symptoms, while others repeatedly return to use or experience more substantial withdrawal.
High-potency extracts, 7-OH, alcohol or benzodiazepine use, previous opioid addiction, significant medical or mental health concerns, polysubstance use, and uncertainty about product contents can make professional assessment especially important.
Does Suboxone treat kratom addiction?
Buprenorphine-containing medications such as Suboxone are not FDA-approved specifically for kratom dependence or problematic kratom use. Case reports and clinical literature describe buprenorphine being used for selected patients, but controlled evidence for kratom-related problems without a co-occurring opioid use disorder remains limited. PubMed Central (PMC)
If someone also has opioid use disorder, treatment is different because buprenorphine is an FDA-approved evidence-based medication for OUD. A clinician should determine whether medication treatment is appropriate based on the individual’s diagnoses and history.
Can kratom be dangerous when mixed with other drugs?
Yes. Risk can increase when kratom or 7-OH is combined with opioids, alcohol, benzodiazepines, other sedatives, stimulants, prescription medications, or unidentified substances.
Recent poison-center data found that multiple substances were involved in the majority of reported kratom-associated deaths, reinforcing the importance of evaluating the full pattern of substance use. CDC
Should naloxone be given during a suspected kratom or 7-OH overdose?
Tennessee behavioral-health officials advise giving naloxone when overdose is suspected because an opioid may be involved and additional medical treatment may be necessary. Call 911, give naloxone if available, stay with the person, and follow emergency-dispatch instructions. Tennessee State Government
Does Brooks Healing Center treat 7-OH dependence?
Yes. Brooks evaluates substance-use problems involving traditional kratom, extracts, concentrated 7-OH, and related patterns of use.
Treatment recommendations are based on withdrawal, product exposure, other substance use, medical and mental health needs, previous treatment, and the overall clinical picture rather than assuming all kratom-related products should be treated identically.
Does insurance cover kratom addiction treatment?
Coverage depends on the health plan, medical necessity, recommended level of care, network status, and individual benefits. Brooks’ admissions team can verify insurance benefits before treatment and explain the information provided by the insurer.
Sources
National Center for Complementary and Integrative Health. (n.d.). Kratom. National Institutes of Health.
https://www.nccih.nih.gov/health/Kratom
U.S. Food and Drug Administration. (n.d.). FDA and kratom.
https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
U.S. Food and Drug Administration. (2025). Products containing 7-OH can cause serious harm.
https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm
U.S. Drug Enforcement Administration. (2026, July 1). DEA to temporarily schedule 7-OH and related substances to protect public safety.
https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public
U.S. Department of Justice. (2026, August 25). Justice Department announces emergency scheduling of three potent opioid compounds.
https://www.justice.gov/opa/pr/justice-department-announces-emergency-scheduling-three-potent-opioid-compounds
Tennessee Department of Mental Health and Substance Abuse Services. (2026). Emerging substances: Kratom.
https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/emerging-substances.html
Utah Department of Agriculture and Food. (2026, July 30). Illegal kratom product sold in Utah County linked to death in Utah.
https://ag.utah.gov/news/illegal-kratom-product-sold-in-utah-county-linked-to-death-in-utah/
Rogers, J. M., Weiss, S. T., & Epstein, D. H. (2024). Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency. Drug and Alcohol Dependence, 260, 111329.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11493341/
Smith, K. E., Epstein, D. H., & Weiss, S. T. (2024). Controversies in assessment, diagnosis, and treatment of kratom use disorder. Current Psychiatry Reports, 26, 487–496.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11344726/
Stanciu, C. N., Gnanasegaram, S. A., Ahmed, S., & Penders, T. (2019). Kratom withdrawal: A systematic review with case series. Journal of Psychoactive Drugs, 51(1), 12–18.
https://pubmed.ncbi.nlm.nih.gov/30614408/
Broyan, V. R., Brar, J. K., Allgaier, T., & Allgaier, J. (2023). Successful management of kratom use disorder with buprenorphine and naloxone. Cureus, 15(5), e38877.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10386870/